Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim
نویسندگان
چکیده
BACKGROUND Immune thrombocytopenia (ITP) in dogs is analogous to that in humans. Romiplostim, a novel thrombopoietin receptor (TPO-R) agonist, is currently used for the treatment of refractory ITP in humans, but not in dogs. Here, we describe the response to romiplostim in five dogs with refractory ITP. Five dogs with severe and refractory ITP (three primary and two secondary) received romiplostim subcutaneously. Four dogs were administered 3-5 μg/kg and one dog received 10-13 μg/kg body weight once weekly. RESULTS Romiplostim was well-tolerated and administration was associated with an increase in platelet counts in all five dogs. Four of the five dogs entered remission and relapses were not observed over a follow-up period of 3-10 months. CONCLUSIONS Romiplostim is effective in the treatment of ITP in dogs at least as well as in humans. This finding may help to develop and use new therapeutics for ITP in dogs and humans.
منابع مشابه
Erratum to: treatment of 5 dogs with immune-mediated thrombocytopenia using romiplostim
Erratum: n.b. The errors and associated corrections described in this document concerning the original manuscript were accountable to the production department handling this manuscript, and thus are no fault of the authors of this paper. Additionally, the online manuscript has now been updated with these corrections accordingly. The original version of the manuscript [1] contained incorrectly f...
متن کاملImmune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro.
Primary immune thrombocytopenia is an autoimmune disease mediated by antiplatelet autoantibodies that cause platelet destruction and suppression of platelet production. In vitro effects of autoantibodies on megakaryocyte production and maturation have been reported recently. However, the impact of these autoantibodies on crucial megakaryocyte functions, proplatelet formation and subsequent plat...
متن کاملTotal remission of severe immune thrombocytopenia after short term treatment with romiplostim
Immune thrombocytopenia (ITP) in adults is an acquired chronic immune-mediated disorder defined by isolated thrombocytopenia. In recent years, an improved understanding of the pathophysiology of ITP has been achieved and it is now accepted that the disorder is due to increased platelet destruction and decreased platelet production from megakary-ocytes. Thrombopoietin (TPO)-receptor agonists (ro...
متن کاملMyelofibrosis Associated with Romiplostim Treatment in a Patient with Immune Thrombocytopenia
Immune thrombocytopenia is characterized by antibody-mediated platelet destruction and insufficient platelet production resulting in isolated thrombocytopenia in the absence of underlying cause. Despite many treatment options, low-to-intermediate rates of remission and high rates of resistance to treatment are seen. Approximately 20% of patients do not attain a hemostatic platelet count after s...
متن کاملManagement of immune thrombocytopenia--something old, something new.
For most of my career, the management of immune thrombocytopenia has evolved from clinical experience rather than clinical evidence. When I was a medical student at Ohio State University in 1960, my mentors were shifting their initial treatment for immune thrombocytopenia from splenectomy to the recently available glucocorticoids.1 Over the next 40 years, although multiple other treatments were...
متن کامل